Abstract Session
Fibrosing rheumatic diseases (scleroderma, MCTD, IgG4-related disease, scleroderma mimics)
Oliver Distler, MD
Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland
Zurich, Switzerland
Disclosure(s): 4P Pharma: Consultant (Ongoing); AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Acceleron: Consultant (Ongoing); Alcimed: Consultant (Ongoing); Altavant: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AnaMar: Consultant (Ongoing); Arxx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Blade: Consultant (Ongoing); Boehringer-Ingelheim: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Corbus: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); Galapagos: Consultant (Ongoing); Galderma: Consultant (Ongoing); Glenmark: Consultant (Ongoing); Gossamer: Consultant (Ongoing); Kymera: Consultant (Ongoing); Lupin: Consultant (Ongoing); Medscape: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Miltenyi Biotec: Consultant (Ongoing); Mitsubishi Tanabe: Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Prometheus: Consultant (Ongoing); Redxpharma: Consultant (Ongoing); Roivant: Consultant (Ongoing); Topadur: Consultant (Ongoing)